BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8391738)

  • 1. Towards vaccines against human papillomavirus type-16 genital infections.
    Cason J; Khan SA; Best JM
    Vaccine; 1993; 11(6):603-11. PubMed ID: 8391738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer, human papillomavirus and vaccines.
    Khan SA
    Clin Oncol (R Coll Radiol); 1993; 5(6):386-90. PubMed ID: 8305362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.
    Stanley MA
    Expert Rev Vaccines; 2003 Jun; 2(3):381-9. PubMed ID: 12903803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
    Cornelison TL
    Curr Opin Oncol; 2000 Sep; 12(5):466-73. PubMed ID: 10975555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
    Gérard CM; Baudson N; Kraemer K; Bruck C; Garçon N; Paterson Y; Pan ZK; Pardoll D
    Vaccine; 2001 Mar; 19(17-19):2583-9. PubMed ID: 11257396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccines.
    Stanley MA
    Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer.
    Gissmann L; Jochmus I; Nindl I; Müller M
    Ann N Y Acad Sci; 1993 Aug; 690():80-5. PubMed ID: 8396380
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
    Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
    Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological response to HPV 16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer.
    Ghosh AK; Smith NK; Stacey SN; Glew SS; Connor ME; Arrand JR; Stern PL
    Int J Cancer; 1993 Feb; 53(4):591-6. PubMed ID: 8382193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies of human papilloma vaccines in cervical cancer.
    Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
    Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
    [No Abstract]   [Full Text] [Related]  

  • 11. Overview of vaccinology with special reference to papillomavirus vaccines.
    Hilleman MR
    J Clin Virol; 2000 Oct; 19(1-2):79-90. PubMed ID: 11091151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
    Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillomavirus vaccines in clinical trials.
    Galloway DA
    Lancet Infect Dis; 2003 Aug; 3(8):469-75. PubMed ID: 12901889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
    Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
    Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
    Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
    Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of vaccination against HPV infections in cervix carcinoma].
    Gissmann L
    Zentralbl Gynakol; 2001 May; 123(5):299-301. PubMed ID: 11449623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
    Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
    J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
    J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.